BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:ChemBio seminar by Prof. Derek Pratt (Uni Ottawa) - CH-635
DTSTART:20240625T104500
DTEND:20240625T114500
DTSTAMP:20260916T055834Z
UID:8a5a6a2a92bd650e7a892204be1c20b4d71c340e03f7caa2ae01fef6
CATEGORIES:Conferences - Seminars
DESCRIPTION:Prof. Derek Pratt\nTitle: The Chemical Basis of Ferroptosis\, 
 Development of Tools to Study it and Design of Compounds to Inhibit it\n\n
 Abstract:\nThe accumulation of oxidized lipids has long been implicated in
  a vast array of diseases\, but has more recently been shown to drive a sp
 ecific type of cell death called ferroptosis. Over the years\, we have wor
 ked to elucidate the molecular mechanisms of  the archetype ferroptosis i
 nhibitors\, ferrostatin-1 and liproxstatin-1\,[1] and delineate the roles 
 of enzyme-mediated and spontaneous lipid peroxidation on the initiation an
 d propagation of ferroptosis.[2] In this lecture we will recount these adv
 ances\, which were enabled by the concepts and tools of physical organic c
 hemistry\, and that lead to the development of high-throughput methods to 
 monitor phospholipid peroxidation in model membranes and mammalian cells\,
  including the FENIX (Fluoresence-ENabled Inhibited autoXidation) assay.[3
 ][4] We will describe how FENIX made possible the characterization of mult
 iple endogenous ferroptosis suppression systems which either synthesize or
  regenerate inhibitors of lipid peroxidation\,[5\, 6] including ferroptosi
 s suppressor protein-1.[7]\,[8] and clinical candidates for treatments of 
 ferroptosis-driven diseases\, including the metal thiosemicarbazone CuATSM
 .[9] Lastly we will show how we have built upon these insights to develop 
 the most potent ferroptosis inhibitors to date\,[10] which have recently b
 een validated in vivo and now serves as promising lead compounds for thera
 peutic development for indications wherein ferroptosis has been implicated
 .\n\n1. ACS Cent Sci 2017\, 3:232–243. https://doi.org/10.1021/acscentsc
 i.7b00028\n2. ACS Cent Sci 2018\, 4:387–396. https://doi.org/10.1021/acs
 centsci.7b00589\n3. Cell Chem Biol 2019\, 26:1594-1607.e7. https://doi.org
 /10.1016/j.chembiol.2019.09.007\n4. ACS Chem Biol 2022\, 18: 461-571. http
 s://doi.org/10.1021/acschembio.2c00897\n5. Nat Chem Biol 2020\, 16:1351–
 1360. https://doi.org/10.1038/s41589-020-0613-y\n6. J Am Chem Soc 2022\, 1
 44:15825–15837. https://doi.org/10.1021/jacs.2c06804\n7. Nature 2019\, 5
 75:693–698. https://doi.org/10.1038/s41586-019-1707-0\n8. Nature 2022\, 
 608:778–783. https://doi.org/10.1038/s41586-022-05022-3\n9. J Am Chem So
 c 2021\, 143:19043–19057. https://doi.org/10.1021/jacs.1c08254\n10. J Am
  Chem Soc 2022\, 144:14706–14721. https://doi.org/10.1021/jacs.2c05252\n
  \nSpeaker's biography:\nDerek is an Ottawa native – born and raised 
 – and attended Carleton University\, from which he graduated with Highes
 t Honours in Chemistry in 1999. A life-changing experience as an undergrad
 uate researcher with Dr. Keith Ingold motivated Derek to pursue a career i
 n research. Supported by a NSERC Julie Payette post-graduate scholarship\,
  he attended Vanderbilt University for his Ph.D. studies under the supervi
 sion of Professor Ned Porter. He then carried out post-doctoral research a
 t the University of Illinois at Urbana-Champaign with Professor Wilfred va
 n der Donk\, where he was supported by a Jane Coffin Childs Fund fellowshi
 p. Excited to return to Canada\, Derek began his independent career in 200
 5 at Queen's University as Canada Research Chair in Free Radical Chemistry
 \, which he renewed following his recruitment to the University of Ottawa 
 in 2010. He was promoted to Full Professor in 2016 and became University R
 esearch Chair in Free Radical Chemistry in 2021. Among several recognition
 s for research excellence\, Derek has been a recipient of the Keith Fagnou
  (2015) and Bernard Belleau (2024) awards from the Canadian Society for Ch
 emistry and the Bessel Prize of the Alexander von Humboldt foundation (201
 9). In addition to his academic duties\, Derek is the scientific co-founde
 r and head of chemistry of Prothegen Inc.\, which develops therapeutics ba
 sed on the modulation of ferroptotic cell death. Derek currently serves as
  a member of NSERC's Chemistry Evaluation Group and is an Associate Editor
  for Science Advances\, the open-access extension of Science magazine.\
 n\nLab website: www.theprattgroup.org\n 
LOCATION:CE 1 5 https://plan.epfl.ch/?room==CE%201%205
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR